Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats

International Journal of Neuropsychopharmacology

Volumn 10, Issue 6, 2007, Pages 727-739

  Bouwmeester, Hans ^a   Gerrits, Mirjam A F M ^a   Roozemond, John G ^a   Snapper, Jolanda ^a   Ronken, Eric ^b   Kruse, Chris G ^b   Westenberg, Herman G M ^a   Van Ree, Jan M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Amygdala; Animal model; Cannabinoid; Development; Dopamine; Schizophrenia

Indexed keywords

BRAIN MONOAMINE; CANNABINOID; CANNABINOID RECEPTOR; DOPAMINE RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BRAIN BIOPSY; BRAIN TISSUE; CHEMICAL ANALYSIS; COGNITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXCITOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HYPERACTIVITY; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; METABOLITE; NERVE CELL DIFFERENTIATION; NEUROTRANSMISSION; NEWBORN DISEASE; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEUS ACCUMBENS; PERINATAL PERIOD; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT; SCHIZOPHRENIA; STRIATE CORTEX; SYMPTOMATOLOGY;

AMYGDALA; ANIMALS; ANIMALS, NEWBORN; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; DOPAMINE; ENDOCANNABINOIDS; EXCITATORY AMINO ACID AGONISTS; HYDROXYINDOLEACETIC ACID; IBOTENIC ACID; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; NOREPINEPHRINE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SEROTONIN;

EID: 35649016076     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706007346     Document Type: Article

References (74)

1. Alquicer G, Silva-Gómez AB, Peralta F, Flores G (2004). Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. International Journal of Developmental Neuroscience 22, 103-111.
2. Arsenault L, Cannon M, Witton J, Murray RM (2002). Causal association between cannabis and psychosis: examination of the evidence. British Medical Journal 325, 1199.
3. 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sciences 35, 1885-1893.
4. Bouwmeester H, Smits K, Van Ree JM (2002a). Neonatal development of projections to the basolateral amygdala from prefrontal and thalamic structures in rat. Journal of Comparative Neurology 450, 241-2559.
5. Bouwmeester H, Wolterink G, Van Ree JM (2002b). Neonatal development of projections from the basolateral amygdala to prefrontal, striatal, and thalamic structures in the rat. Journal of Comparative Neurology 442, 239-249.
6. Carr DB, Sesack SR (2000). Projections from the rat prefrontal cortex to the ventral tegmental area : target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. Journal of Neuroscience 20, 3864-3873.
7. Chen JF, Aloyo VJ, Weiss B (1993). Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience 54, 669-680.
8. Chen NN, Pan WH (2000). Regulatory effects of D2 receptors in the ventral tegmental area on the mesocorticolimbic pathway. Journal of Neurochemistry 74, 2576-2582.
9. Civelli O, Bunzow JR, Grandy DK (1993). Molecular diversity of the dopamine receptors. Annual Review of Pharmacology and Toxicology 33, 281-307.
10. Daenen EW, Van der Heyden JA, Kruse CG, Wolterink G, Van Ree JM (2001). Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus. Brain Research 918, 153-165.
11. Daenen EW, Wolterink G, Gerrits MA, Van Ree JM (2002a). The effects of neonatal lesions in the amygdala or ventral hippocampus social behaviour later in life. Behavioural Brain Research 136, 571-582.
12. Daenen EW, Wolterink G, Gerrits MA, Van Ree JM (2002b). Amygdala or ventral hippocampal lesions at two early stages of life differentially affect open field behaviour later in life ; an animal model of neurodevelopmental psychopathological disorders. Behavioural Brain Research 131, 67-78.
13. Daenen EW, Wolterink G, Van Der Heyden JA, Kruse CG, Van Ree JM (2003a). Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic startle response; implications for an animal model of neurodevelopmental disorders like schizophrenia. European Neuropsychopharmacology 13, 187-197.
14. Daenen EW, Wolterink G, Van Ree JM (2003b). Hyperresponsiveness to phencyclidine in animals lesioned in the amygdala on day 7 of life. Implications for an animal model of schizophrenia. European Neuropsychopharmacology 13, 273-279.
15. Dawe GS, Huff KD, Vandergriff JL, Sharp T, O'Neill MJ, Rasmussen K (2001). Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biological Psychiatry 50, 510-520.
16. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Biological Psychiatry 53, 585-592.
17. Deutch AY, Clark WA, Roth RH (1990). Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Research 521, 311-315.
18. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, Sokoloff P (2000). Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. Journal of Neuroscience 20, 8677-8684.
19. Diergaarde L, Gerrits MA, Brouwers JP, Van Ree JM (2005). Early amygdala disrupts performance on medial prefrontal cortex-related tasks but spares spatial learning and memory in the rat. Neuroscience 130, 581-590.
20. Diergaarde L, Gerrits MA, Stuy A, Spruijt BM, Van Ree JM (2004). Neonatal amygdala lesions and juvenile isolation in the rat : differential effects on locomotor and social behavior later in life. Behavioural Neuroscience 118, 298-305.
21. Doherty MD, Gratton A (1997). NMDA receptors in nucleus accumbens modulate stress-induced dopamine release in nucleus accumbens and ventral tegmental area. Synapse 26, 225-234.
22. Duncan GE, Sheitman BB, Lieberman JA (1999). An integrated view of pathophysiological models of schizophrenia. Brain Research Reviews 29, 250-264.
23. 11C]raclopride. Archives of General Psychiatry 47, 213-219.
24. Friedman JI, Adler DN, Davis KL (1999). The role of norepinephrine in the pathophysiology of cognitive disorders : potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biological Psychiatry 46, 1243-1252.
25. Gingrich JA, Caron MG (1993). Recent advances in the molecular biology of dopamine receptors. Annual Review of Neuroscience 16, 299-321.
26. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114.
27. Goto Y, O'Donnell P (2004). Prefrontal lesion reverses abnormal mesoaccumbens response in an animal model of schizophrenia. Biological Psychiatry 55, 172-176.
28. Groenewegen HJ, Wright CI, Uylings HB (1997). The anatomical relationships of the prefrontal cortex with limbic structures and the basal ganglia. Journal of Psychopharmacology 11, 99-106.
29. Hall WD (2006). Cannabis use and the mental health of young people. Australian & New Zealand Journal of Psychiatry 40, 105-113.
30. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience 11, 563-583.
31. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences USA 87, 1932-1936.
32. Jackson ME, Moghaddam B (2001). Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. Journal of Neuroscience 21, 676-681.
33. Joel D, Weiner I (2000). The connections of the dopaminergic system with the striatum in rats and primates : an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96, 451-474.
34. Kalivas PW (1993). Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Research Reviews 18, 75-113.
35. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? : a new hypothesis. American Journal of Psychiatry 158, 360-369.
36. Krystal JH, D'Souza DC, Madonick S, Petrakis IL (1999). Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 35 (Suppl.), S35-S49.
37. Lahti RA, Roberts RC, Tamminga CA (1995). D2-family receptor distribution in human postmortem tissue : an autoradiographic study. Neuroreport 6, 2505-2512.
38. Laruelle M, Abi-Dargham A, Van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, et al. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences USA 93, 9235-9240.
39. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (2001). Elevated endogenous cannabinoids in schizophrenia. Neuroscience 103, 9-15.
40. Lipska BK, Lerman DN, Khaing ZZ, Shannon Weickert C, Weinberger DR (2003a). Gene expression in dopamine and GABA systems in an animal model of schizophrenia : effects of antipsychotic drugs. European Journal of Neuroscience 18, 391-402.
41. Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR (2003b). The neonatal ventral hippocampal lesion model of schizophrenia : effects on dopamine and GABA mRNA markers in the rat midbrain. European Journal of Neuroscience 18, 3097-3104.
42. Lipska BK, Weinberger DR (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23, 223-239.
43. Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli O, Akil H, Watson SJ (1990). Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary : an in situ hybridization-receptor autoradiographic analysis. Journal of Neuroscience 10, 2587-2600.
44. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002). Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience 5, 267-271.
45. Moldrich G, Wenger T (2000). Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21, 1735-1742.
46. 11C]N-methylspiperone. Psychiatry Research 61, 67-83.
47. Oak JN, Oldenhof J, Van Tol HH (2000). The dopamine D(4) receptor : one decade of research. European Journal of Pharmacology 405, 303-327.
48. Paxinos G, Watson C (2004). The Rat Brain in Stereotaxic Coordinates. The New Coronal Set (5th edn). Orlando, USA: Academic Press.
49. Rodriguez De Fonseca F, Gorriti MA, Bilbao A, Escuredo L, Garcia-Segura LM, Piomelli D, Navarro M (2001). Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotoxicity Research 3, 23-35.
50. Seeman P (1987). Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133-152.
51. Seeman P, Kapur S (2000). Schizophrenia : more dopamine, more D2 receptors. Proceedings of the National Academy of Sciences USA 97, 7673-7675.
52. Semple DM, McIntosh AM, Lawrie SM (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 19, 187-194.
53. Sesack SR, Pickel VM (1990). In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Research 527, 266-279.
54. Sheldon T (2003). Review shows that cannabis use is a risk factor for schizophrenia. British Medical Journal 325, 1070.
55. Smith Y, Kieval JZ (2000). Anatomy of the dopamine system in the basal ganglia. Trends in Neuroscience 23, S28-S33.
56. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146-151.
57. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ (1998). Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2-, and D4-like receptors. Neuroscience 83, 169-176.
58. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL (1997). Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology 17, 186-196.
59. Terpstra J, Gispen-de Wied CC, Broekhoven MH, Frankhuijzen AC, Kahn RS, Van Ree JM, Wiegant VM (2003). Attenuated stress responsiveness in an animal model for neurodevelopmental psychopathological disorders. European Neuropsychopharmacology 13, 249-256.
60. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervouw system. Neuroscience 83, 393-411.
61. Tzschentke TM (2001). Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Progress in Neurobiology 63, 241-320.
62. Tzschentke TM, Schmidt WJ (2000). Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Critical Reviews in Neurobiology 14, 131-142.
63. Van der Stelt M, Di Marzo V (2003). The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology 480, 133-150.
64. Van Eden CG, Uylings HB (1985). Cytoarchitectonic development of the prefrontal cortex in the rat. Journal of Comparative Neurology 241, 253-267.
65. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614.
66. Veen ND, Selten JP, Van der Tweel I, Feller WG, Hoek HW, Kahn RS (2004). Cannabis and age at onset in schizophrenia. American Journal of Psychiatry 161, 501-506.
67. Verwer RW, Van Vulpen EH, Van Uum JF (1996). Postnatal development of amygdaloid projections to the prefrontal cortex in the rat studied with retrograde and anterograde tracers. Journal of Comparative Neurology 376, 75-96.
68. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives in General Psychiatry 44, 660-669.
69. Wolterink G, Daenen LE, Dubbeldam S, Gerrits MA, Van Rijn R, Kruse CG, Van der Heijden JA, Van Ree JM (2001). Early amygdala damage in the rat as a model for neurodevelopmental psychopathological disorders. European Neuropsychopharmacology 11, 51-59.
70. Wood GK, Lipska BK, Weinberger DR (1997). Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Developmental Brain Research 101, 17-25.
71. Yamamoto BK, Novotney S (1998). Regulation of extracellular dopamine by the norepinephrine transporter. Journal of Neurochemistry 71, 274-280.
72. 3H]YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord. Journal of Comparative Neurology 344, 121-136.
73. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 28, 355-360.
74. Zhang K, Tarazi FI, Davids E, Balldessarini RJ (2002). Plasticity of daopmine D4 receptors in rat forebrain: Temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. Neuropsychopharmacology 26, 625-633.